TVGN

Tevogen Bio Holdings Inc. (TVGN) - 10-K Summary

Business Context and Reporting Period

Company: Tevogen Bio Holdings Inc.
Reporting Period: Fiscal year ended December 31, 2024.
Business Overview: Tevogen is a clinical-stage immunotherapy company developing off-the-shelf, precision T cell therapies using its proprietary ExacTcell technology. The company focuses on infectious diseases (specifically COVID-19 and Long COVID), cancer, and neurological disorders. Its lead product candidate, TVGN 489, is an allogeneic cytotoxic CD8+ T cell therapy designed for immunocompromised and high-risk elderly patients with COVID-19. The company completed a Phase 1 proof-of-concept trial in January 2023 with positive safety and efficacy signals and plans to advance to pivotal trials.

Key Financial Metrics

Note: The 2024 net loss was significantly reduced compared to 2023 due to a $48.5 million non-cash gain from the change in fair value of convertible promissory notes upon conversion during the business combination. Operating expenses increased primarily due to $40.8 million in stock-based compensation and $7.5 million in merger transaction costs.

Material Changes vs. Prior Period

• Business Combination: Completed a reverse recapitalization with Semper Paratus Acquisition Corporation on February 14, 2024. The company became a publicly traded entity on Nasdaq (TVGN).
• Capital Structure: Converted outstanding convertible promissory notes into common stock. Issued Series A and Series C Preferred Stock totaling $8.0 million in proceeds. Entered a Loan Agreement providing up to $36.0 million in term loans.
• Expense Volatility: Operating expenses surged from $8.8 million in 2023 to $53.6 million in 2024. This increase was driven largely by non-cash stock-based compensation ($40.8 million) triggered by the liquidity event of the merger and transaction costs.
• Liquidity Position: Cash on hand remained low at $1.3 million, but liquidity is supported by the Loan Agreement and committed grant funding.

Guidance, Outlook, and Risks

Outlook and Funding: The company expects to incur significant losses for the foreseeable future. Management believes current cash, the Loan Agreement (allowing $1.0 million monthly draws), and a committed $8.0 million grant from KRHP LLC (affiliated with a major investor) will fund operations for at least the next 12 months. The company does not plan to initiate new clinical trials until additional funding is secured.

Key Risks and Contingencies:

• Liquidity Risk: The company relies on the $8.0 million grant (partially received) and the Loan Agreement to meet liquidity needs. Failure to secure additional capital could force delays in development.
• Development Risk: TVGN 489 is in clinical development; there is no guarantee of regulatory approval or commercial success. The company has no approved products.
• Internal Controls: The company identified material weaknesses in internal control over financial reporting, specifically regarding segregation of duties and risk assessment processes.
• Concentration of Ownership: The CEO and principal stockholders control approximately 90% of outstanding shares, limiting minority shareholder influence.

Investor Verification Checklist

• Grant Funding Status: Verify the receipt and terms of the remaining $8.0 million grant from KRHP LLC, which is critical for the company's runway.
• Loan Agreement Terms: Review the specific covenants, interest rates (payable in stock), and conversion options of the $36.0 million Loan Agreement with The Patel Family, LLP.
• Internal Control Remediation: Monitor the company's progress in remediating the identified material weaknesses in internal controls over financial reporting.
• Preferred Stock Dilution: Assess the potential dilution from the Series A and Series C Preferred Stock, including their dividend rates and conversion features.
• Clinical Trial Timeline: Confirm the timeline and regulatory strategy for the planned pivotal trial of TVGN 489 in patients with B-cell malignancies.